Abstract: Anomalous or weakened sense of self was central to early theories of schizophrenia. Recent studies have also documented disturbances in body ownership and increased susceptibility for dissociative experiences, such as the out-of-body experience in individuals with schizophrenia, but further research is necessary to clarify components of bodily self-disturbances in the schizophrenia spectrum, and the stability of these experiences over time. With respect to methodology, self-disturbances research in schizophrenia tends to rely exclusively on verbal self-report questionnaires and interviews. Given that individuals with schizophrenia suffer from language and communication difficulties, verbal self-report measures may be insufficient. To bridge this gap, we have developed a new picture-based instrument, the Benson et al. Body Disturbances Inventory (B-BODI), designed to quantify bodily self-disturbances with respect to the frequency and vividness of these experiences, as well as the degree of distress associated with them. Drawings that depicted different aspects of aberrant bodily self-experiences were presented with accompanying captions. Participants were asked to indicate the frequency, vividness, and distressfulness of the experience captured by the picture using a 5-point scale. Individuals with schizophrenia, older healthy controls, and college students participated in two alternative versions of the B-BODI. Participants were also asked to complete a battery of established questionnaires that probed psychosis proneness and a range of self, body, and perceptual aberrations. The results suggest that the B-BODI is a useful tool that accurately captures bodily self-disturbances and has the potential to predict psychosis risk in healthy young individuals. Furthermore, anomalous self-disturbances seem to be relatively stable across time in individuals with chronic schizophrenia.
Schizophrenia is a debilitating psychotic disorder, which affects about 1% of the world's population (Murray, Jones, Susser, Van Os, & Cannon, 2002) . Disturbed sense of self was paramount to the concept of schizophrenia from the beginning. Bleuler (1950) coined the term schizophrenia to indicate a basic disorder of selfhood (schizo = split, phrene = mind). However, the importance of sense of self as a central component of the study of schizophrenia has been somewhat diminished in the literature, even though many of the symptoms of schizophrenia may stem from self-disturbance, including passivity, delusions of control, and third person voices (Sass & Parnas, 2003) . Nevertheless, with the advent of empirical measures designed to experimentally quantify self-disturbances, the scientific study of the sense of self in schizophrenia has begun to flourish again. Indeed, a recent meta-analysis conducted by Hur, Kwon, Lee, and Park (2014) indicates a "crisis" of selfdisorders in patients with schizophrenia, finding large effect sizes for body ownership disturbances and medium effect sizes for faulty sense of agency and subjective experiences of anomalous sense of self. Thus, bodily self-distortions are present in patients with full-blown schizophrenia.
A core component of selfhood is a stable, continuous sense of the body across time, which is disrupted in schizophrenia as indicated by a wide range of bodily aberrations. First, important evidence of abnormal processing bodily signals in schizophrenia comes from exteroceptive, proprioceptive, and interoceptive studies that indicate reduced pain sensitivity (Fishbain, 1982; Dworkin, 1994; Rosenthal, Porter, & Coffey, 1990; Singh, Giles, & Nasrallah, 2006) , reduced tactile sensitivity (Chang & Lenzenweger, 2001 , 2004 Lenzenweger, 2000) , impaired proprioception (Michael & Park, 2016; Thakkar, Nichols, McIntosh, & Park, 2011) , and interoceptive deficits (Dawson et al., 2010; Lewis, Sherwood, Moselhy, & Ellis, 2001; Roux, Christophe, & Passerieux, 2010; Williams et al., 2007) . Second, schizophrenia is associated with abnormal processing of one's own face (Irani et al., 2006) and difficulties recognizing one's own voice (Johns et al., 2001) . Third, patients with schizophrenia exhibit abnormal self-other boundary. For example, they are prone to out-of-body experiences (e.g., Blackmore, 1986; Thakkar et al., 2011) .
Although there is ample clinical evidence for the contribution of self-disturbances to schizophrenia pathology (e.g., Brent, Seidman, Thermenos, Holt, & Keshavan, 2014; Nelson, Thompson, & Yung, 2012; Raballo & Parnas, 2012) , much of the research relies on self-report questionnaires or interviews. Current self-report measures that quantify anomalous sense of self include the Dissociative Experiences Scale II (DES-II; Carlson & Putnam, 1993) , the Perceptual Aberration Scale (PAS; Chapman, Chapman, & Raulin, 1978) , and the Self-Experience Lifetime Frequency (SELF) Scale (Heering et al., 2016) . Additionally, the Examination of Anomalous Self-Experiences (EASE) is a semi-structured interview that seeks to assess unusual self-experiences across the schizophrenia spectrum. The EASE yields good psychometric properties, including adequate internal consistency (Raballo & Parnas, 2012) , and interrater reliability (Møller, Haug, Raballo, Parnas, & Melle, 2011) . Furthermore, scores on the EASE have been found to predict transition to psychosis in individuals who are at risk of schizophrenia (Nelson et al., 2012) , and it is specific to schizophrenia and not other types of psychosis (e.g., bipolar disorder; Nelson, Thompson, & Yung, 2013) . While these available self-report measures and interviews are useful in documenting anomalous self-experiences across the schizophrenia spectrum, there are limitations. Given the reduced insight and communication ability in individuals with schizophrenia, complete reliance on verbal self-reports may restrict our capacity to measure and quantify the extent of self-disturbances.
The aim of the present study was to develop and validate a new picture-based inventory of bodily self-disturbances, the Benson et al. Body Disturbances Inventory (B-BODI), which utilizes drawings that depict unusual bodily experiences in order to elicit participants' responses. Each drawing corresponds to a written statement about a bodily experience and if the participant endorses it, further questions are asked on the frequency, vividness (intensity), and their distress about this experience. B-BODI items probe dissociations, flexibility of the body boundary, body aberrations, loss of body ownership, loss of agency, self-other transformations, feeling-of-presence, anomalous sense of time, and forms of autoscopic hallucinations. Using visual depictions of anomalous experiences to probe selfdisturbances is useful for several reasons. Body aberrations and self-disturbances are difficult to verbalize regardless of diagnosis. Therefore, providing pictures in addition to verbal captions supports communication of these experiences. In addition, using pictures might help reduce potential confounds that sometimes arise in literal translations of verbal questionnaires, which would be useful for cultural comparisons.
For all of the individual B-BODI pictures, we predicted that participants with schizophrenia would endorse significantly more items, and also score higher on frequency, distress, and vividness (intensity) as a result of having these experiences more often (contributing to the frequency score), feeling as if they were stressful (contributing to the distress score), and imagining them more vividly (e.g., based on the findings of enhanced imagery in individuals with schizophrenia; Benson & Park, 2013 ; contributing to the vividness score). The same hypothesis and predictions were made for individuals at increased risk for schizophrenia compared to those at lower risk. Lastly, we collected data in two phases for the B-BODI development using similar but not identical pictures in a sample of individuals with schizophrenia to examine the stability of bodily self-aberrations.
Methods
Participants B-BODI 1: 26 participants with schizophrenia, 17 older adult healthy controls (HCs) who were age-matched to the patient group, and 66 healthy young undergraduate students were recruited from the Nashville area. The undergraduate sample was 77% female, 65% Caucasian, and 90% right-handed with a mean age of 20 years (SD = 2 years). Schizophrenia patients met the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; 5th ed., American Psychiatric Association [APA], 2013) diagnostic criteria for schizophrenia and all were taking antipsychotic medications. Older HC participants did not meet any DSM-5 criteria for Axis I disorders (APA, 2013) and had no history of psychosis in their families. The schizophrenia and HC groups were matched for age, sex, race, and handedness. Table 1 presents the demographic and clinical information.
B-BODI 2: 19 participants diagnosed with schizophrenia, 28 older HC participants, and 231 university students were recruited from the Nashville area. Table 1 presents demographic information for the schizophrenia and HC groups. The undergraduate sample was 59% Caucasian and 88% right-handed with a mean age of 19 years (SD = 2 years). Schizophrenia patients met the DSM-5 diagnostic criteria for schizophrenia (APA, 2013) and all were taking antipsychotic medication. Older HC participants had no DSM-5 Axis I disorders (APA, 2013), and had no history of psychosis in their families (Table 1) .
B-BODI 1 and 2: 18 individuals with schizophrenia completed the two different versions of the B-BODI so that we could compare their scores to assess stability of selfdisturbances in schizophrenia.
Exclusion criteria for all potential participants were as follows: history of head injury, neurological disorders, and current substance use. All participants gave written informed consent. The schizophrenia and older HC groups were paid. Undergraduate students received course credit for their participation. This protocol was approved by the Vanderbilt University Institutional Review Board. Please see Benson (2017) for full details of the methods.
Procedure
After obtaining informed consent, participants completed a battery of questionnaires and the B-BODI. Individuals with schizophrenia and older HC participants were also interviewed with the Structured Clinical Interview for the DSM-5 (First, Spitzer, Gibbon, & Williams, 2002a , 2002b to confirm diagnostic status. The two phases of the B-BODI data collection took place approximately 18 months apart.
Measures

B-BODI
The B-BODI was designed to quantify anomalous bodily self-experiences in both clinical and healthy populations. Participants were explicitly instructed to answer all items without referring to times if/when they had been under the influence of drugs. The B-BODI was administered to participants online through REDcap software (https:// projectredcap.org/). Table 2 presents the verbal captions for the 21 items and Figure 1 presents the pictures. (7) 102 (9) 108 (7) 103 (9) Note. B-BODI = Benson et al. Body Disturbances Inventory; HCs = healthy controls; BPRS = Brief Psychiatric Rating Scale; SAPS = Scale for the Assessment of Positive Symptoms; SANS = Scale for the Assessment of Negative Symptoms; CPZE = chlorpromazine-equivalent; NA = not applicable. a IQ was estimated with the National Adult Reading Test (Spreen & Strauss, 1998) . b Handedness was assessed with the Edinburgh Inventory (Oldfield, 1971) . * Significant group differences at p < .05.
B-BODI 1
In the first version of the B-BODI, we used 21 pictures used at the University Hospital of Zürich Neuropsychology Unit for assessing anomalous bodily self-experiences of neurological patients during clinical interviews. Each picture was accompanied by a statement that closely captured the depicted experience. Participants were asked to examine the picture and read the caption to answer the following questions. First, we asked if the participant had ever had an experience described by the picture and the caption (True/False choice). An endorsement (True response) received 1 point and a False response received zero points. There are 21 pictures in the B-BODI and thus the total endorsement sum ranges from 0 to 21. If the participant endorsed the experience, he/she answered the frequency question. Participants were asked how often they had had this experience in the past month. They chose from Not in the past month (scored 1), 1-2 times in the past month (scored 2), Once per week (scored 3), A few times per week (scored 4), to Daily (scored 5). For the distress question, participants chose from Not applicable (scored 0), and Strongly disagree (scored 1), Disagree (scored 2), Neutral (scored 3), Agree (scored 4), or Strongly agree (scored 5). For the intensity and vividness of these experiences, we asked, "How vividly do you recall the image of this experience?" Response options were: 0% (not at all) (scored 1), 25% (scored 2), 50% (scored 3), 75% (scored 4), and 100% (very) (scored 5). Thus, for each item, the range of score could vary between 0 and 13. Total B-BODI 1 score was I have sometimes had the feeling that one of my arms or legs is disconnected from the rest of my body.
Perceptual Aberration Scale (Chapman et al., 1978) 4 Sometimes when falling asleep or when waking from sleep, I experience a brief period during which I am unable to move, even though I am awake and conscious of my surroundings.
Waterloo Unusual Sleep Experiences Questionnaire (Cheyne, 2002) 5 Do you ever find that your experience of time changes dramatically?
Cardiff Anomalous Perception Scale (Bell, Halligan, & Ellis, 2005) 6 Have you ever had the feeling of the presence of another being, even if you know that no one is there?
Schizotypal Personality Questionnaire (Raine, 1991) 7 I have had experiences when I felt as if I were someone else. Temporal Lobe Scale (Makarec & Persinger, 1985) 8 I have had experiences (not related to drugs) where I felt as though I was floating through the air or being transported through time.
Wisconsin Experience Questionnaire (Kihlstrom et al., 1989 ) 9
Have you ever experienced or seen your "doppelganger" or "double"?
Original item
10
Have you ever felt that you looked unreal when you looked at yourself in the mirror?
Kings Schizotypy Questionnaire (Jones et al., 2000) 11 I have been visited by Spiritual Beings. Personal Philosophy Inventory (Persinger & Makarec, 1991) 
12
I have had an "out of the body" experience during which my mind seems to, or actually has, left my body.
Boundary Questionnaire (Hartmann, 1991) 13 Have you ever felt like you could see multiple duplicates of yourself (or someone else)?
Original item 14 Do you ever have the sensation that your limbs might not be your own or might not be properly connected to your body?
Cardiff Anomalous Perception Scale (Bell et al., 2006) 15 Do you ever find the appearance of things or people seems to change in a puzzling way, e.g., distorted shapes or sizes or color?
Cardiff Anomalous Perception Scale (Bell et al., 2006) 16 I've had the momentary feeling that I might not be human. Magical Ideation Scale (Eckblad & Chapman, 1983) 
17
I have heard an inner voice call my name.
Temporal Lobe Scale (Makarec & Persinger, 1985) 18 Do you ever have the sensation that your body, or a part of it, is changing or has changed shape?
Cardiff Anomalous Perception Scale (Bell et al., 2006) 19 At times I have felt as if I were coming apart. Boundary Questionnaire (Hartmann, 1991) 
20
On occasions, I have seen a person's face in front of me when no one was in fact there.
Revised Launay Slade Hallucination Scale (Morrison, Wells, & Nothard, 2002) 
21
Have you ever felt that thoughts were being put inside your head by some outside force?
Scale for the Assessment of Positive Symptoms (Andreasen, 1984) Note. B-BODI = Benson et al. Body Disturbances Inventory. the sum of all the scores across the 21 items, ranging from 0 to a maximum of 273 (21 × 13). We also calculated "Current endorsements," which is the sum of endorsements that participants reported had occurred in the past month, and "Current distressing endorsements," which is the sum of endorsements participants reported in the past month that they also rated as distressing, by choosing Agree or Strongly agree to the distress questions. Additionally, we calculated an "Endorsement with distress" variable. The items for which the participant endorsed Agreed or Strongly agreed to the distress question were summed.
B-BODI 2
For the second version of the B-BODI, the captions were unchanged but we replaced all the pictures with similar drawings by four local artists in order to remove the possibility that some of the pictures used in the B-BODI 1 might have been copyrighted. We also added four pictures of "normal" bodily experiences that almost all humans experience at some point in their lives (headaches, scratching, butterflies in the stomach, and itchiness) and we used these four pictures as control items. Scoring of the B-BODI 2 was identical to that for the B-BODI 1, except for the four control items. The four new control items of the B-BODI 2 were not counted in the total score, and instead they served as a form of validity check. If participants did not endorse at least one of these items, then their total score was deemed invalid, as headaches, scratching, butterflies in the stomach, and itchiness are universal. Figure 1 presents the pictures used in the B-BODI 2.
Self-report questionnaires
Participants' scores on the B-BODI were compared with measures of convergent validity, including the DES-II (Bernstein & Putnam, 1986; Carlson & Putnam, 1993) , PAS (Chapman et al., 1978) , Schizotypal Personality Questionnaire (SPQ; Raine, 1991) , and the Prodromal Questionnaire, Brief Version (PQ-B; Loewy, Pearson, Vinogradov, Bearden, & Cannon, 2011) for B-BODI 1 and B-BODI 2. For the B-BODI 2, the Temporal Lobe Scale (TLS; Persinger, 1984), and the SELF Scale (Heering et al., 2016) were added.
For the B-BODI 2, participants also completed measures for divergent validity analyses, including the Physical Anhedonia Scale (Chapman, Chapman, & Raulin, 1976) , the Hypomanic Personality Scale (Eckblad & Chapman, 1986) , and the Autism Spectrum Quotient (Baron-Cohen, Wheelwright, Skinner, Martin, & Clubley, 2001).
Designation of putative high-and low-risk groups among healthy undergraduate participants
The PQ-B (Loewy et al., 2011 ) was used to ascertain high psychosis risk and low psychosis risk groups according to the published criteria. Those who scored higher than six distressing endorsements on the PQ-B were considered to be in the high-risk group. The low PQ-B group was defined by scoring up to two distressing endorsements on the PQ-B (Loewy et al., 2011) . According to the B-BODI 1, 29 students met the criteria for the high-risk group, with 42 in the low-risk group. According to the B-BODI 2, 16 students met the criteria for the high-risk group and 43 met the criteria for the low-risk group. Those who scored in between the low-and high-risk groups were not included in the comparison analyses. There were no statistical differences in age, education, handedness, or proportion of women when comparing high-versus low-risk groups according to the B-BODI 1 and B-BODI 2 (p > .2 for all comparisons).
Clinical symptoms of individuals with schizophrenia
Symptoms of individuals with schizophrenia were assessed with the Brief Psychiatric Rating Scale (Overall & Gorham, 1962) , the Scale for the Assessment of Positive Symptoms (SAPS; Andreasen, 1984) , and the Scale for the Assessment of Negative Symptoms (SANS; Andreasen, 1983) . Medication information was used to compute the chlorpromazine-equivalent dose (Andreasen, Pressler, Nopoulos, Miller, & Ho, 2010) . Table 1 presents the clinical characteristics of the schizophrenia group.
Data analysis
All significance tests were 2-tailed, unless otherwise indicated. Prior to analysis, the distribution of each variable was checked for the presence of a non-normal distribution and descriptive statistics were outlined to determine skewness and kurtosis of each variable. If variables had skewness or kurtosis values greater than AE2, they were considered not normal (Field, 2000 (Field, , 2009 Trochim & Donnelly, 2006) . Finally, tests of normality (Shapiro-Wilks tests) were conducted on the variables in question to determine if a variable had a normal distribution. Since most of the variables utilized in the current study were considered non-normal (i.e., B-BODI variables, PQ-B, PAS scores, and DES-II scores), with the B-BODI skewed heavily towards zero, as expected, non-parametric tests were utilized.
Cronbach's coefficient α was used to examine internal consistency of the B-BODI, and split-half reliability analyses were conducted in SPSS, as described below. Spearman's correlations were used to examine the relationship between B-BODI scores and the DES-II (Carlson & Putnam, 1993 ) and the schizophrenia-spectrum measures listed above. Further analyses were conducted using Spearman's correlations when overlapping item content among questionnaires was removed to ensure that correlations among related measures were not merely a result of overlapping items, but rather that the measures were similar in constructs (see Benson, 2017 ). Spearman's correlations between two B-BODI versions were calculated to assess stability of scores among the 18 individuals with schizophrenia.
Kruskal-Wallis tests were used to compare data among the three groups (i.e., low-risk, high-risk, and schizophrenia status). Mann-Whitney U tests were used to compare the data between two groups (i.e., schizophrenia compared to HCs, and high-risk compared to low-risk). Effect sizes (r) were calculated after conducting Mann-Whitney U tests using the formula [Z / √ N], where Z represents the converted U value from the Mann-Whitney U test in SPSS.
Results
The descriptive statistics from the two versions of the B-BODI from all participants are presented in Table 3 .
Reliability of the B-BODI
Internal consistency analyses were conducted for the two B-BODI administrations. For B-BODI 1, Cronbach's coefficient α was .891. For B-BODI 2, Cronbach's coefficient α was .867. Thus, both B-BODI administrations achieved acceptable levels of internal consistency, which some might even classify as "good" (George & Mallery, 2003) . Split half reliability analyses were also conducted for both administrations of the B-BODI. The B-BODI 1 was split into two halves, the first with 11 items (Cronbach's α = .807) and the second with 10 items (Cronbach's α = .796). The correlation between the two B-BODI 1 halves was .821, the Spearman-Brown coefficient was .901, and the Guttman split-half coefficient was .889. The same procedure was used for the B-BODI 2, including the four new control items. The B-BODI 2 was split into two halves, the first with 13 items and the second with 12 items. The correlation between the two B-BODI 2 forms was .751, the Spearman-Brown coefficient was .858, and the Guttman split-half coefficient was .844.
Stability of the B-BODI
We were able to assess test-retest reliability for the B-BODI using a sample size of 18 schizophrenia patients who participated in both and we found acceptable reliability (ρ = .80, p < .0001). When we compared the B-BODI scores across the two versions with a repeated-measures analysis of variance, we found no significant differences in the total scores, F(1, 17) = 0.0016, p > .86, or the current endorsement scores, F(1, 17) = 0.058, p > .33, in those patients who participated in both versions, administered approximately 18 months apart. Figure 2 presents the B-BODI scores of the 18 schizophrenia patients who participated in both versions.
Validity of the B-BODI
B-BODI 1
Spearman's rank correlations were conducted to assess convergent validity with related measures. Total B-BODI 1 scores were positively correlated with total PQ-B scores (ρ = .73, p < .0001), SPQ scores (ρ = .63, p < .001), DES-II scores (ρ = .44, p < .01), and PAS scores (ρ = .58, p < .001), even after correcting for multiple comparisons (p < .05). Further, total B-BODI 1 scores were positively correlated with Brief Psychiatric Rating Scale scores (ρ = .70, p < .0001) and SAPS scores (ρ = .70, p < .001). The SANS did not correlate with total B-BODI 1 scores (ρ = .04, p = .86). There was no relationship between chlorpromazine-equivalent dose and B-BODI 1 total scores (ρ = -.116, p = .62) in this patient group. Among healthy participants, there was a positive correlation between B-BODI 1 total score and SPQ interpersonal factor (ρ = .47, p < .001).
It must be noted that the questionnaires we administered contain many overlapping items because they probe similar domains. After removing overlapping items from multiple questionnaires, we conducted the same correlations as above. Without the overlapping items, B-BODI 1 total scores were still positively correlated with DES-II total scores (ρ = .45, p < .01), PAS scores (ρ = .51, p < .01), SPQ total scores (ρ = .64, p < .01), and PQ-B scores (ρ = .72, p < .0001), and all remained significant even after correcting for multiple comparisons with Bonferroni (p < .05).
B-BODI 2
For the schizophrenia group, total B-BODI 2 scores were positively correlated with positive symptoms (SAPS scores; ρ = .67, p < .01) and inversely correlated with negative symptoms (SANS scores; ρ = -.59, p < .05). Chlorpromazine-equivalent dose was unrelated to any of the B-BODI 2 variables (p > .10).
We conducted all correlational analyses after removing overlapping items from questionnaires. B-BODI 2 total scores were strongly associated with PQ-B in the undergraduate sample (ρ = .73, p < .0001). B-BODI 2 total scores were also positively correlated with total scores on the SPQ (ρ = .67, p < .0001), DES-II (ρ = .62, p < .0001), TLS (ρ = .69, p < .0001), PAS (ρ = .68, p < .0001), and SELF Scale (ρ = .62, p < .01) even after using Bonferroni correction for multiple comparisons. B-BODI 2 total scores were unrelated to Physical Anhedonia Scale score.
Group differences
B-BODI 1
As predicted, patients with schizophrenia scored higher than age-matched HC participants on total B-BODI 1 scores (U = 83.5, p = .007, r = .43). Schizophrenia patients also had significantly higher total DES-II scores (U = 45, p = .001, r = .49). As predicted, when comparing the young student sample divided into low-risk and high-risk groups, we saw greater B-BODI 1 scores in the high-risk group (U = 202, p < .0001, r = .56). Finally, total B-BODI 1 scores differentiated the psychosis spectrum, χ 2 (2) = 28.9, p < .0001, with schizophrenia patients demonstrating the highest scores on the B-BODI 1 (Median = 47), followed by the high-risk group (Median = 24), age-matched HCs (Median = 5), and the low-risk group (Median = 4.5). Table 4 presents a summary of the scores.
B-BODI 2
The schizophrenia group scored higher than HCs on total B-BODI 2 (U = 134, p = .004, r = .44). The schizophrenia group endorsed more B-BODI 2 items than HCs, reported greater frequency of the B-BODI 2 items, more distress associated with the B-BODI 2 items, and more vivid recollection of the B-BODI 2 item experiences (p < .05). Also as predicted, patients with schizophrenia had higher levels of distressing B-BODI 2 experiences than HCs in general, more current levels of B-BODI 2 experiences, and more currently distressing B-BODI 2 experiences than HCs (p < .05). For the four control items about normal bodily sensations (headache, scratching, butterflies in the stomach, and itchiness), HCs scored higher than patients (U = 141, p = .001, r = .28) indicating their awareness of ordinary bodily sensations. Students who were designated to the high-risk group scored significantly higher than those in the low-risk group on total scores of the B-BODI 2 (U = 108, p < .0001, r = .52). There were no differences between the two risk groups on the B-BODI 2 control items (headache, scratching, butterflies in the stomach, and itchiness; U = 323, p = .582, r = .07).
Finally, when comparing schizophrenia patients and the two risk groups from the student population, we also found differences in the B-BODI 2 total scores, χ 2 (2) = 22.3, p < .0001. Surprisingly, the high-risk group scored the highest on the B-BODI 2, with a median of 39, while the schizophrenia group had a median of 25, and the low-risk group a median of 10. The difference between schizophrenia patients and the young, high-risk group was not significantly different, however (U = 349, p = .301, r = .13). This finding suggests that those who may carry latent liability for schizophrenia seem to be experiencing significant bodily self-disturbances already at this stage. There are two things of note. First, the student groups were much younger than the patients and the older HCs. Second, healthy participants were not taking any psychotropic medication. Therefore, increased B-BODI 2 scores among the high-risk group in this study are unlikely to have been caused by medication. Table 4 presents a summary of scores.
Discussion
The major goal of this study was to develop and validate a picture-based inventory of bodily self-disturbances (the B-BODI), which may be useful for detecting and quantifying anomalous experiences that are difficult to verbally describe. Captions accompanied drawings that depict and the capture essence of self-disturbances in order to aid one's ability to communicate one's internal experiences. We also aimed to examine the stability of bodily aberrations across time in individuals with schizophrenia using the B-BODI.
B-BODI scores were robustly correlated with the DES-II (Bernstein & Putnam, 1986; Carlson & Putnam, 1993) , PAS (Chapman et al., 1978) , PQ-B (Loewy et al., 2011) , SPQ (Raine, 1991) , SAPS (Andreasen, 1984) , SELF Scale (Heering et al., 2016) , and TLS (Persinger, 1984) , supporting convergent validity. In addition, the B-BODI showed good discriminant validity; it was not correlated with measures of negative schizophrenia-schizotypy scales, such as the Physical Anhedonia Scale, in healthy participants, and was inversely related to negative symptoms (SANS scores) in schizophrenia patients. Furthermore, the B-BODI showed good internal consistency and acceptable reliability indices by way of split-half reliability, and also some promising results for test-retest reliability for the B-BODI in patients with schizophrenia, indicating stability of self-disturbance in this population. Lastly, B-BODI scores were stable across 18 months in individuals with schizophrenia, suggesting that these experiences may not fluctuate very much. However, the sample size of the patient group was small and we were only able to test those with chronic schizophrenia. Therefore, it is unknown whether B-BODI scores are stable across time in first-episode or early psychosis patients. There are several limitations to this study. Our assessment of psychosis risk should be supplemented by clinically validated interviews, such as the Structured Interview for Prodromal Symptoms (Miller et al., 2003) . Although the PQ-B is a reliable screening instrument, it is not possible to ascribe high-risk status with confidence. However, the fact that the B-BODI 2 scores of the students in the high-risk group were not significantly different from those of the patients is noteworthy and must be followed up with the Structured Interview for Prodromal Symptoms. Another limitation of this study is that only self-report measures were used to validate the B-BODI. However, a recent study (Benson & Park, 2018) showed that a proprioceptive-tactile illusion that engenders the feeling that one's body part is changing (Pinocchio Illusion) is associated with the B-BODI scores. Future studies need to incorporate both experimental approaches and phenomenological instruments to assess self-disturbances in order to increase the accuracy of the quantification of internal, subjective experiences.
Self-disturbances are common features of a wide range of neuropsychiatric conditions, including autism, eating disorders, and bipolar disorder. Our understanding of the nature of the bodily self will be enhanced by investigating common and separable mechanisms underlying different types of selfdisturbances. Lastly, the role of bodily self-disturbances in the prodromal phase of schizophrenia must be investigated systematically to determine whether instruments such as the B-BODI can help detect the impending signs of psychosis earlier and more accurately. This would be important for initiating and choosing appropriate intervention strategies.
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